Compare Nasdaq100 ETF (QQQ) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nasdaq100 ETF vs Repligen Corporation Common Stock — how do they compare? Nasdaq100 ETF trades at $720.5 (market cap $506.12B), while Repligen Corporation Common Stock trades at $178.2 (market cap $11.31B). The key difference: Nasdaq100 ETF is far larger — about 44.7× Repligen Corporation Common Stock's market cap, and Nasdaq100 ETF is more actively traded (51,534,028 versus 1,216,919). Which is the better fit depends on your goals — on Pluang, investors hold Nasdaq100 ETF for 163 Days and Repligen Corporation Common Stock for 0 Days on average.
| QQQ | RGEN | |
|---|---|---|
Market Cap | $506.12B | $11.31B |
Volume | 51,534,028 | 1,216,919 |
52-Week High | $759.66 | $194.57 |
52-Week Low | $558.34 | $102.87 |
Typical Hold Time | 163 Days | 0 Days |
Sector | — | Health |
Enterprise Value | — | $11.20B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QQQ trades at $743.57, down 0.32% on the day, with a bullish technical signal from moving averages despite neutral oscillators. The ETF shows mixed analyst sentiment with a 50% buy and 50% sell consensus. Recent news highlights QQQ's strong decade-long performance and ongoing innovation with new international ETF launches, though concerns about AI market valuations and expense ratios compared to competitors like QQQM persist.
Outlook remains cautiously optimistic given QQQ's tech-heavy exposure and AI-driven growth potential, but risks include market volatility from Fed rate hikes, high concentration in tech stocks, and valuation concerns. The dividend of $0.75 payable in October 2026 provides minor income support.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nasdaq100 ETF
The ETF is designed to track the performance of the securities and the stocks in the NASDAQ-100 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on QQQ →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
